A61K 31/4985
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K31/4985 (Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems) appears on 2,127 US grants and 4,172 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,127
- Published applications
- 4,172
- Assignees
- 1,414
- Inventors
- 8,763
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 15 | 0 |
| 1999 | 8 | 0 |
| 2000 | 7 | 0 |
| 2001 | 10 | 7 |
| 2002 | 15 | 24 |
| 2003 | 13 | 50 |
| 2004 | 33 | 83 |
| 2005 | 10 | 28 |
| 2006 | 50 | 39 |
| 2007 | 7 | 39 |
| 2008 | 19 | 46 |
| 2009 | 17 | 61 |
| 2010 | 14 | 64 |
| 2011 | 24 | 80 |
| 2012 | 37 | 115 |
| 2013 | 57 | 165 |
| 2014 | 90 | 215 |
| 2015 | 137 | 233 |
| 2016 | 151 | 251 |
| 2017 | 167 | 253 |
| 2018 | 185 | 244 |
| 2019 | 154 | 237 |
| 2020 | 138 | 246 |
| 2021 | 160 | 249 |
| 2022 | 119 | 243 |
| 2023 | 122 | 259 |
| 2024 | 123 | 324 |
| 2025 | 118 | 323 |
| 2026 | 112 | 294 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Sirt6 activators6 Oct 2026US 12,753,180 B2Board of Regents, The University of Texas System
- Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses6 Oct 2026US 12,753,187 B2Merck Sharp & Dohme Corp.
- Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations29 Sep 2026US 12,746,268 B2Nymox Corporation
- Compositions and methods for treating cancer22 Sep 2026US 12,740,981 B2The Regents of the University of Michigan
- Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators22 Sep 2026US 12,741,971 B2AstraZeneca AB
- Combination therapy for pulmonary hypertension8 Oct 2026US 2026/0306461 A1Vivus, Inc.
- Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase8 Oct 2026US 2026/0306487 A1Genentech, Inc.
- Functional protective agent for organ or tissue8 Oct 2026US 2026/0306488 A1Jellice Co., Ltd.
- Organic compounds8 Oct 2026US 2026/0306489 A1Intra-Cellular Therapies, Inc.
- Substituted oxoisoindolinyl piperidine-2,6-dione compounds and aza analogs thereof8 Oct 2026US 2026/0308147 A1
Most cited
By later US patents
- Combination treatment for depression150US 6,436,938 B1Pfizer Inc. · 2002
- Pyrazole compound and medicinal composition containing the same142US 7,429,609 B2Eisai R&D Management Co., Ltd. · 2008
- Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes140US 6,699,871 B2Merck & Co., Inc. · 2004
- Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family123US 6,265,410 B1Warner-Lambert Company · 2001
- Delivery of erectile dysfunction drugs through an inhalation route120US 6,803,031 B2Alexza Molecular Delivery Corporation · 2004